<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07383</article-id><article-id pub-id-type="doi">10.7554/eLife.07383</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Human Biology and Medicine</subject></subj-group></article-categories><title-group><article-title>Registered report: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-30268"><name><surname>Lesnik</surname><given-names>Jake</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30269"><name><surname>Antes</surname><given-names>Travis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-30272"><name><surname>Kim</surname><given-names>Jeewon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-16421"><name><surname>Griner</surname><given-names>Erin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-30275"><name><surname>Pedro</surname><given-names>Luisa</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="groupAu1"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con6"/></contrib><aff id="aff1"><label>1</label><institution>System Biosciences, LLC</institution>, <addr-line><named-content content-type="city">Mountain View</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Transgenic Research Center</institution>, <institution>Stanford University School of Medicine</institution>, <addr-line><named-content content-type="city">Stanford</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution>University of Virginia</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Green</surname><given-names>Michael R</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Howard Hughes Medical Institute, University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff id="aff6"><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United State</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff id="aff7"><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff id="aff8"><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff id="aff9"><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff id="aff10"><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff id="aff11"><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>tim@cos.io</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>01</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e07383</elocation-id><history><date date-type="received"><day>09</day><month>03</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2015</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>Alečković</surname><given-names>M</given-names></name><name><surname>Lavotshkin</surname><given-names>S</given-names></name><name><surname>Matei</surname><given-names>I</given-names></name><name><surname>Costa-Silva</surname><given-names>B</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G</given-names></name><name><surname>Hergueta-Redondo</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>García-Santos</surname><given-names>G</given-names></name><name><surname>Ghajar</surname><given-names>CM</given-names></name><name><surname>Nitadori-Hoshino</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>C</given-names></name><name><surname>Badal</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>VR</given-names></name><name><surname>Skog</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RN</given-names></name><name><surname>Brady</surname><given-names>MS</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Bromberg</surname><given-names>J</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name></person-group>. <year>2012</year>. <article-title>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</article-title>. <source>Nature Medicine</source>. <volume>18</volume>. doi:<pub-id pub-id-type="doi">10.1038/nm.2753</pub-id></mixed-citation></p></fn></history><permissions><copyright-statement>© 2016, Lesnik et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Lesnik et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-07383-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.07383.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (<xref ref-type="bibr" rid="bib1">Errington et al., 2014</xref>). This Registered Report describes the proposed replication plan of key experiments from “Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET” by Peinado and colleagues, published in Nature Medicine in 2012 (<xref ref-type="bibr" rid="bib7">Peinado et al., 2012</xref>). The key experiments being replicated are from Figures 4E, as well as Supplementary Figures 1C and 5A. In these experiments, Peinado and colleagues show tumor exosomes enhance metastasis to bones and lungs, which is diminished by reducing <italic>Met</italic> expression in exosomes (<xref ref-type="bibr" rid="bib1">Peinado et al., 2012</xref>). The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link> and the results of the replications will be published in <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.07383.001">http://dx.doi.org/10.7554/eLife.07383.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>methodology</kwd><kwd>exosomes</kwd><kwd>metastasis</kwd><kwd>receptor tyrosine kinase</kwd><kwd>MET</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient><institution>Reproducibility Project: Cancer Biology</institution></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Exosomes are nanovesicles up to 100 nm in size that are derived from endosomal membranes and secreted by cells as a means of intercellular communication (<xref ref-type="bibr" rid="bib6">Mathivanan et al., 2010</xref>). They contain a wide array of cargo including proteins, cytokines, and nucleic acids (<xref ref-type="bibr" rid="bib4">Kharaziha et al., 2012</xref>). Recently, exosomes have been shown to play multiple roles in promoting carcinogenesis, including the regulation of metastatic niche formation, regulation of tumor immune response, and chemotherapeutic resistance (<xref ref-type="bibr" rid="bib9">Tickner et al., 2014</xref>). Peinado and colleagues reported that exosomes derived from melanoma cells promoted metastasis through education of bone marrow-derived cells in order to prime the pre-metastatic niche and increase vascularization. They further showed that exosome-mediated metastasis was dependent on expression of MET in exosomes, and that MET protein was increased in exosomes found in patients with advanced melanoma (<xref ref-type="bibr" rid="bib7">Peinado et al., 2012</xref>). MET is an oncogenic receptor tyrosine kinase that promotes proliferation, motility, and migration, and is often aberrantly activated in tumors (<xref ref-type="bibr" rid="bib3">Gherardi et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Trusolino et al., 2010</xref>). These findings indicate that exosomal MET may be a potential therapeutic target or biomarker for metastatic disease.</p><p>Supplementary Figure 1C characterizes exosomes isolated from B16-F10 melanoma cells using electron microscopy imaging and Western blotting for exosome protein markers. Supplementary Figure 5A further characterizes these exosomes by assessing the levels of MET and pMET after shRNA-mediated depletion of <italic>MET</italic> in B16-F10 cells. These figures are essential to reproduce as they validate the expression of key proteins in exosomes that will subsequently be used to replicate Figure 4E. These experiments will be replicated in Protocols 1 and 2.</p><p>In Figure 4E, <xref ref-type="bibr" rid="bib7">Peinado et al. (2012)</xref> reported that reduction of MET protein in melanoma exosomes reduced metastasis of B16-F10 melanoma cells to lung and bone (<xref ref-type="bibr" rid="bib7">Peinado et al., 2012</xref>). Mice were pre-treated with exosomes isolated from B16-F10 melanoma cells expressing shRNAs directed against <italic>Met</italic> or control shRNAs, and then B16-F10 cells were injected subcutaneously. Primary tumor growth and metastasis to lungs and bone were assessed by luciferase imaging. This key experiment tests one of the central findings of the paper, namely that MET is necessary for melanoma exosome-mediated promotion of metastasis. This experiment will be replicated in Protocol 3.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Protocol 1: Lentiviral knockdown of <italic>Met</italic> or non-silencing control in B16-F10 cells</title><p>This protocol utilizes shRNA to knock down <italic>Met</italic> in B16-F10 cells. This experiment generates key reagents (B16-F10 shMet and B16-F10 shScramble) that will subsequently be used in Protocols 2 and 3.</p><sec id="s2-1-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment will be conducted once.<list list-type="bullet"><list-item><p>This experiment will generate B16-F10 shMet and B16-F10 shScramble stable cells.</p></list-item></list></p></list-item></list><p>Note: Information that these are stable transfectants was communicated by authors.</p></sec><sec id="s2-1-2"><title>Materials and reagents</title><p><table-wrap id="tblu1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>B16-F10 cells</td><td>Cell line</td><td>Original lab</td><td>n/a</td><td>From original lab</td></tr><tr><td>Dulbecco’s modified <break/>Eagle’s medium (DMEM)</td><td>Cell culture</td><td>VWR</td><td>45000-30</td><td>Communicated by authors</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>GE Healthcare (HyClone)</td><td>SH30088.03</td><td>Original catalog number <break/>not specified</td></tr><tr><td>Ultracentrifuge</td><td>Instrument</td><td>Sorval</td><td/><td>SureSpin 630 rotor</td></tr><tr><td>Thick wall ultracentrifuge <break/>tubes</td><td>Labware</td><td colspan="3">Specific brand information will be left up to the discretion of the replicating lab and recorded later</td></tr><tr><td>100X Penicillin/streptomycin</td><td>Cell culture</td><td>Life Technologies</td><td>15140-155</td><td>Communicated by authors</td></tr><tr><td>Phosphate buffered <break/>saline (PBS)</td><td>Cell culture</td><td>Fisher Scientific</td><td>MT-21-040-CM</td><td>Replaces VWR, <break/>cat# 45000-446; <break/>communicated by authors</td></tr><tr><td>Trypsin</td><td>Cell culture</td><td>Invitrogen</td><td>25200-056</td><td>Original brand not specified</td></tr><tr><td>pGIPZ mouse <italic>Met</italic> shRNA <break/>lentiviral particles <break/>(clone ID: V3LMM_456078)</td><td>Lentivirus</td><td>Dharmacon/GE Lifesciences</td><td>VGM5520-200377256</td><td>Original from Thermo, which <break/>was acquired by Dharmcon/GE <break/>Lifesciences</td></tr><tr><td>pGIPZ non-silencing <break/>shRNA lentiviral particles</td><td>Lentivirus</td><td>Dharmacon/GE Lifesciences</td><td>RHS4348</td><td>Original from Thermo, <break/>which was acquired by <break/>Dharmcon/GE Lifesciences</td></tr><tr><td>TransDux</td><td>Cell culture</td><td>System Biosciences</td><td>LV850A-1</td><td>Replaces polybrene</td></tr><tr><td>Fluorescent microscope</td><td>Instrument</td><td>Leica</td><td>DMI300b</td><td>Original instrument not specified</td></tr><tr><td>Puromycin</td><td>Cell culture</td><td>Sigma-Aldrich</td><td>P8833-100MG</td><td>Included during communication <break/>with authors; original brand <break/>not specified</td></tr><tr><td>150-mm tissue culture dish</td><td>Labware</td><td>E &amp; K Scientific</td><td>EK-39160</td><td>Original brand not specified</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-1-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and short tandem repeat (STR) profiling.</p></list-item><list-item><p>Cells maintained in DMEM supplemented with 10% exosome-depleted FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Deplete exosomes from FBS by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Transduce B16-F10 cells with pGIPZ mouse <italic>Met</italic> shRNA (shMet) or pGIPZ non-silencing shRNA (sh Scramble) lentiviral particles following provider standard protocol (see Guide to Lentiviral Packaging and Transduction, System Biosciences) with a multiplicty of infection (MOI) of 10:1 (lentivirus particles:cells) and incubate overnight (16 hr).<list list-type="alpha-lower"><list-item><p>Combine culture medium with TransDux to a 1X final concentration.</p></list-item></list></p></list-item><list-item><p>The next day (16 hr later) replace media.</p></list-item><list-item><p>Determine transduction efficiency by green fluorescent protein (GFP) expression:<list list-type="alpha-lower"><list-item><p>Three d after transduction (when efficiency is anticipated to be near 80–90%), use fluorescent microscopy to image cells to determine transduction efficiency based on percent of GFP-positive cells.<list list-type="roman-lower"><list-item><p>Use untransduced B16-F10 cells as GFP-negative cell population.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>After determining transduction efficiency, replace media supplemented with 1.5 µg/ml of puromycin to select for transduced cells.<list list-type="alpha-lower"><list-item><p>Use untransduced B16-F10 cells as control for puromycin selection treatment.</p></list-item></list></p></list-item><list-item><p>Continue culture and passage of B16-F10 shMet and B16-F10 shScramble stable cells in puromycin for at least 28 d before further analysis.<list list-type="alpha-lower"><list-item><p>After initial selection of 28 d, B16-F10 shMet and B16-F10 shScramble cells should be maintained in puromycin, however when cells are plated for experiments they do not need puromycin added.</p></list-item><list-item><p>Record detailed notes about culturing and passaging of cells, paying particular attention to density.</p></list-item></list></p></list-item></list></sec><sec id="s2-1-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Detailed notes on cell culturing of both stable cell lines generated.</p></list-item><list-item><p>Transduction efficiency as a percentage of GFP-positive cells.</p></list-item><list-item><p>Fluorescent microscopy images of GFP-positive cells.</p></list-item></list></p></list-item><list-item><p>Sample delivered for further analysis:<list list-type="bullet"><list-item><p>B16-F10 shMet and B16-F10 shScramble cells for exosome purification and Western blot analysis of METexpression for Protocol 2.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble cells for exosome purification and mouse injection for Protocol 3.</p></list-item></list></p></list-item></list></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><p>No analysis performed.</p></sec><sec id="s2-1-6"><title>Known differences from the original study</title><p>Similar to the original study, the transduction efficiency, determined by GFP expression, and the knockdown efficiency, determined by Western blot, will be measured (Protocol 2). The original protocol for selecting GFP-positive cells included a step to perform fluorescence-activated cell sorting (FACS) of the population to achieve a 95–99% GFP-positive population prior to puromycin selection (information provided by authors). The replication attempt will not include the FACS sorting step and instead will select the stable cells for at least 28 d before further analysis and will maintain the cell lines when not used in experimental procedures under puromycin selection. All known differences are listed in the Materials and reagents section above with the originally used item listed in the Comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Untransduced B16-F10 cells will be used to confirm the GFP-negative cell population and during puromycin selection to ensure efficient transduction occurs. Detailed cell culture notes will be recorded and made available to monitor growth rates of B16-F10 shScramble and B16-F10 shMet cells. All of the raw data will be uploaded to the project page on the Open Science Framework (OSF) (<ext-link ext-link-type="uri" xlink:href="https://osf.io/ewqzf/">https://osf.io/ewqzf/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-2"><title>Protocol 2: Exosome purification and Western blot analysis of MET and phospho-MET expression</title><p>This protocol isolates exosomes from B16-F10 shScramble and B16-F10 shMet cells and then utilizes Western blot to characterize protein expression in cells generated in Protocol 1 and exosomes purified from this protocol. MET and pMET protein expression will be determined to verify MET knock down in exosomes, and exosome markers will also be assessed. This experiment will replicate Figures S5A and S1C (right panel).</p><sec id="s2-2-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment to be repeated a total of three times for a minimum power of 99%.<list list-type="bullet"><list-item><p>See Power calculations section for details.</p></list-item></list></p></list-item><list-item><p>Each experiment has four cohorts:<list list-type="bullet"><list-item><p>Cohort 1: B16-F10 shScramble cells</p></list-item><list-item><p>Cohort 2: B16-F10 shMet cells</p></list-item><list-item><p>Cohort 3: Purified exosomes from B16-F10 shScramble cells</p></list-item><list-item><p>Cohort 4: Purified exosomes from B16-F10 shMet cells</p></list-item></list></p></list-item><list-item><p>Each cohort is probed for:<list list-type="bullet"><list-item><p>HSC70 (exosome marker)</p></list-item><list-item><p>TSG101 (exosome marker)</p></list-item><list-item><p>CD63 (additional exosome marker)</p></list-item><list-item><p>MET</p></list-item><list-item><p>pMET Tyr1234/5</p></list-item><list-item><p>Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; control)</p></list-item></list></p></list-item></list></sec><sec id="s2-2-2"><title>Materials and reagents</title><p><table-wrap id="tblu2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>B16-F10 shScramble cells</td><td>Cell line</td><td>n/a</td><td>n/a</td><td>Generated in Protocol 1</td></tr><tr><td>B16-F10 shMet cells</td><td>Cell line</td><td>n/a</td><td>n/a</td><td>Generated in Protocol 1</td></tr><tr><td>Dulbecco’s modified Eagle’s <break/>medium (DMEM)</td><td>Cell culture</td><td>VWR</td><td>45000-30</td><td>Communicated by authors</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>GE Healthcare (HyClone)</td><td>SH30088.03</td><td>Original catalog number <break/>not specified</td></tr><tr><td>100X Penicillin/streptomycin</td><td>Cell culture</td><td>Life Technologies</td><td>15140-155</td><td>Communicated by authors</td></tr><tr><td>Trypsin</td><td>Cell culture</td><td>Invitrogen</td><td>25200-056</td><td>Original brand not specified</td></tr><tr><td>150 mm tissue culture dishes</td><td>Labware</td><td>E &amp; K Scientific</td><td>EK-39160</td><td>Original brand not specified</td></tr><tr><td>10 mm tissue culture dishes</td><td>Labware</td><td>Fisher Scientific</td><td>08-772-4F</td><td>Original brand not specified</td></tr><tr><td>50 ml centrifuge tubes</td><td>Labware</td><td>Fisher Scientific</td><td>14-959-49A</td><td>Original brand not specified</td></tr><tr><td>Ultracentrifuge</td><td>Instrument</td><td>Sorval</td><td/><td>SureSpin 630 rotor</td></tr><tr><td>Thick wall ultracentrifuge tubes</td><td>Labware</td><td colspan="3">Specific brand information will be left up to the discretion of the replicating lab <break/>and recorded later</td></tr><tr><td>Phosphate buffered saline (PBS)</td><td>Cell culture</td><td>Fisher Scientific</td><td>MT-21-040-CM</td><td>Replaces VWR, cat# 45000-446; <break/>communicated by authors</td></tr><tr><td>Radioimmunoprecipitation <break/>assay (RIPA) buffer</td><td> Buffer</td><td>Sigma-Aldrich</td><td>R0278</td><td>Original catalog number <break/>not specified</td></tr><tr><td>Complete protease inhibitor <break/>tablets</td><td>Inhibitor</td><td>Roche</td><td>04693116001</td><td>Original catalog number <break/>not specified</td></tr><tr><td>Bicinchoninic acid (BCA) protein <break/>determination kit</td><td>Reporter assay</td><td>Pierce</td><td>23227</td><td>Original catalog number <break/>not specified</td></tr><tr><td>4X Laemmli sample buffer</td><td>Buffer</td><td>Bio-Rad</td><td>161-0747</td><td>Original brand not specified</td></tr><tr><td>Nanoparticle characterization system</td><td>Instrument</td><td>NanoSight</td><td>LM10</td><td/></tr><tr><td>Nanoparticle Tracking Analysis</td><td>Software</td><td>NanoSight</td><td>Version 2.3</td><td>Original version not specified</td></tr><tr><td>Sodium dodecyl sulfate polyacrylamide <break/>gel electrophoresis (SDS-PAGE) <break/>gradient gels</td><td>Western materials</td><td>BioRad</td><td>456-1094</td><td>Original catalog number <break/>not specified</td></tr><tr><td>Pre-stained protein molecular <break/>weight marker</td><td>Western materials</td><td>BioRad</td><td>161-0377</td><td>Original brand not specified</td></tr><tr><td>Electrophoresis buffer with SDS</td><td>Buffer</td><td>BioRad</td><td>161-0772</td><td>Original brand not specified</td></tr><tr><td>10X Electrophoresis buffer <break/>Tris/glycine/SDS</td><td>Instrument</td><td>BioRad</td><td>165-8004</td><td>Original brand not specified</td></tr><tr><td>Methanol</td><td>Chemical</td><td>Fisher Scientific</td><td>A412-4</td><td>Included during communication <break/>with authors; original brand <break/>not specified</td></tr><tr><td>Wet transfer system</td><td>Instrument</td><td>BioRad</td><td>170-3930</td><td>Original was a semi-dry system</td></tr><tr><td>Immobilon-P polyvinylidene <break/>difluoride (PVDF) membrane</td><td>Western materials</td><td>Millipore</td><td>IPVH10100</td><td>Communicated by authors</td></tr><tr><td>SuperBlock</td><td>Chemical</td><td>Thermo Scientific</td><td>37516</td><td>Original was 2.5% non-fat milk</td></tr><tr><td>Tris-buffered saline (TBS)</td><td>Buffer</td><td>BioRad</td><td>170-6435</td><td>Included during communication <break/>with authors; original brand <break/>not specified</td></tr><tr><td>Tween-20</td><td>Chemical</td><td>Fisher Scientific</td><td>BP337-500</td><td>Included during communication <break/>with authors; original brand <break/>not specified</td></tr><tr><td>Mouse-anti-HSC70</td><td>Antibodies</td><td>Stressgen</td><td>ALX-804-067</td><td>Dilute 1:500; 70 kDa</td></tr><tr><td>Mouse anti-TSG101</td><td>Antibodies</td><td>Santa Cruz</td><td>sc-7964</td><td>Dilute 1:500; 45 kDa</td></tr><tr><td>Rabbit anti-CD63</td><td>Antibodies</td><td>System Biosciences</td><td>EXOAB-CD63A-1</td><td>Dilute 1:1,000; 53 kDa</td></tr><tr><td>Mouse anti-MET</td><td>Antibodies</td><td>Cell Signaling Technology</td><td>3127</td><td>Dilute 1:1,000; 145 kDa</td></tr><tr><td>Rabbit anti-pMET (Tyr1234/5)</td><td>Antibodies</td><td>Cell Signaling <break/>Technology</td><td>3077</td><td>Dilute 1:1,000; 145 kDa</td></tr><tr><td>Rabbit anti-GAPDH</td><td>Antibodies</td><td>Santa Cruz Biotechnology</td><td>sc-25778</td><td>Dilute 1:1,000; 37 kDa</td></tr><tr><td>Sheep anti-mouse-HRP</td><td>Antibodies</td><td>GE Healthcare</td><td>NA931V</td><td>Dilute 1:4,000–1:20,000</td></tr><tr><td>Donkey anti-rabbit-HRP</td><td>Antibodies</td><td>GE Healthcare</td><td>NA934V</td><td>Dilute 1:4,000–1:20,000</td></tr><tr><td>Enhanced chemiluminescent <break/>(ECL) reagent</td><td>Western materials</td><td>Thermo Scientific</td><td>34095</td><td>Included during communication <break/>with authors; original brand <break/>not specified</td></tr><tr><td>ImageJ</td><td>Software</td><td>NIH</td><td>Version 1.48</td><td/></tr></tbody></table></table-wrap></p></sec><sec id="s2-2-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble stable cells were generated in Protocol 1.</p></list-item><list-item><p>All cells maintained in DMEM supplemented with 10% exosome-depleted FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble stable cells should have 1.5 µg/ml puromycin added to medium while maintaining the cell lines that are not used in the experimental procedure.</p></list-item></list><list list-type="order"><list-item><p>Deplete exosomes from FBS by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Grow B16-F10 shScramble and B16-F10 shMet cells for exosome purification and direct lysis.<list list-type="alpha-lower"><list-item><p>For exosome purification plate ~5 x 10<sup>6</sup> cells per 150 mm dish with 25 ml of media. Use two dishes per cell line.</p></list-item><list-item><p>For direct lysis plate ~8–10 x 10<sup>6</sup> cells per 100 mm dish with 10 ml of media. Use one dish per cell line.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble cells do not need puromycin added to plates used in the experimental procedure.</p></list-item></list></p></list-item><list-item><p>Grow exponentially until cells reach 80–90% confluence.<list list-type="alpha-lower"><list-item><p>Culture 100 mm dishes overnight.</p></list-item><list-item><p>Culture 150 mm dishes for 48–72 hr.</p></list-item></list></p></list-item><list-item><p>Directly lyse in 100 mm dishes:<list list-type="alpha-lower"><list-item><p>Wash cells in PBS.</p></list-item><list-item><p>Prepare RIPA buffer and harvest cells directly in lysis buffer.<list list-type="roman-lower"><list-item><p>Add a complete protease inhibitor to RIPA buffer.</p></list-item></list></p></list-item><list-item><p>Clear lysates by benchtop centrifugation at 14,000x<italic>g</italic> for 20 min at 4˚C.</p></list-item><list-item><p>Measure protein concentration of supernatant with a BCA kit following manufacturer’s instructions.</p></list-item><list-item><p>Prepare 30 µg of total protein per sample with 4X Laemmli buffer.<list list-type="roman-lower"><list-item><p>Store at -20˚C until analysis.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Purify exosomes from 150 mm dishes:<list list-type="alpha-lower"><list-item><p>Collect supernatant from cell cultures in 50 ml centrifuge tubes.</p></list-item><list-item><p>Pellet cells from supernatant in a benchtop centrifuge at 500x<italic>g</italic> for 10 min at 4˚C.</p></list-item><list-item><p>Transfer supernatant to thick wall ultracentrifuge tubes.</p></list-item><list-item><p>Remove cell debris by ultracentrifugation at 20,000x<italic>g</italic> for 20 min at 4˚C.</p></list-item><list-item><p>Collect supernatant.</p></list-item><list-item><p>Harvest exosomes by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Resuspend the exosome pellet in 20 ml of PBS.</p></list-item><list-item><p>Pellet exosomes by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Resuspend exosome pellet in 100 µl PBS.<list list-type="roman-lower"><list-item><p>Exosomes can be stored at -20˚C for 2–3 weeks.</p></list-item></list></p></list-item><list-item><p>Measure protein concentration with a BCA kit following manufacturer’s instructions.<list list-type="roman-lower"><list-item><p>Estimated yield of exosomes should be around 1–2 µg/1 x 10<sup>6</sup> cells.</p></list-item></list></p></list-item><list-item><p>Characterize exosome pellet using standard Nanosight NTA analysis.<list list-type="roman-lower"><list-item><p>10–20 µg of exosome protein is needed for analysis.</p></list-item><list-item><p>Report on size distribution and concentration of exosomes.</p></list-item></list></p></list-item><list-item><p>Prepare 30 µg of total protein per sample with 4X Laemmli buffer.<list list-type="roman-lower"><list-item><p>Store at -20˚C until analysis.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Load 30 µg of total protein with sample buffer in each lane on an SDS-PAGE gel with a protein molecular weight marker.</p></list-item><list-item><p>Run electrophoresis at constant voltage (100 V) for ~1–2 hr in 1X electrophoresis buffer following manufacturer instructions.</p></list-item><list-item><p>Transfer gel to membrane using a wet transfer system at constant amperage (350 mA) for 45 min in 1X Tris-glycine buffer supplemented with 20% methanol.<list list-type="alpha-lower"><list-item><p>Pre-soak membrane with methanol and then 1X transfer buffer before assembly.</p></list-item></list></p></list-item><list-item><p>Block membranes in SuperBlock following manufacturer’s instructions.</p></list-item><list-item><p>Probe membranes with the following primary antibodies overnight at 4˚C diluted in SuperBlock.<list list-type="alpha-lower"><list-item><p>mouse anti-HSC70; use at 1:500; 70 kDa</p></list-item><list-item><p>mouse anti-TSG101; use at 1:500; 45 kDa</p></list-item><list-item><p>anti-CD63; use at 1:1000; 53 kDa</p></list-item><list-item><p>mouse anti-MET; use at 1:1000; 145 kDa</p></list-item><list-item><p>rabbit anti-pMET Tyr1234/5; use at 1:1000; 145 kDa</p></list-item><list-item><p>rabbit anti-GAPDH; use at 1:1000; 37 kDa</p></list-item></list></p></list-item><list-item><p>Wash membranes three times 10 min in Ticket Tax Box Service (TTBS).<list list-type="alpha-lower"><list-item><p>TTBS = 1X TBS supplemented with 0.1% tween.</p></list-item></list></p></list-item><list-item><p>Detect primary antibodies with the following secondary antibodies diluted in SuperBlock for 1 hr.<list list-type="alpha-lower"><list-item><p>sheep anti-mouse-HRP; use at 1:4000–1:20,000</p></list-item><list-item><p>donkey anti-rabbit-HRP; use at 1:4000–1:20,000</p></list-item></list></p></list-item><list-item><p>Wash membranes three times for 10 min each in TTBS.</p></list-item><list-item><p>Detect using ECL reagent following manufacturer’s instructions.</p></list-item><list-item><p>Quantify intensities of the immunoreactive bands by densitometry.<list list-type="alpha-lower"><list-item><p>Normalize total MET to GAPDH.</p></list-item><list-item><p>Normalize pMET (Tyr1234/1235) to GAPDH.</p></list-item></list></p></list-item><list-item><p>Repeat independently two additional times.</p></list-item></list></sec><sec id="s2-2-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Exosome characterization data (including protein concentration using a BCA kit).</p></list-item><list-item><p>Images of probed membranes (full images with ladder) (compare to Figure S1C [right panel]).</p></list-item><list-item><p>Quantified levels of total MET and Phospho-MET normalized to GAPDH for all conditions (compare to Figure S5A).</p></list-item></list></p></list-item></list></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><p>This experiment assesses if knockdown of <italic>Met</italic> alters total MET and phospho-MET expression in cells and exosomes. This replication attempt will perform the following statistical analysis:</p><list list-type="bullet"><list-item><p>Statistical analysis:<list list-type="bullet"><list-item><p>One-way multivariate analysis of variance (MANOVA) comparing the relative mean of photon signal for total MET and phospho-MET normalized to GAPDH from B16-F10 shScramble and B16-F10 shMet cells.<list list-type="bullet"><list-item><p>Planned comparisons with the Bonferroni correction:<list list-type="order"><list-item><p>Total MET in B16-F10 shScramble cells compared with B16-F10 shMet cells</p></list-item><list-item><p>Phospho-MET in B16-F10 shScramble cells compared with B16-F10 shMet cells</p></list-item></list></p></list-item></list></p></list-item><list-item><p>One-way MANOVA comparing the relative mean of photon signal for total MET and phospho-MET normalized to GAPDH from B16-F10 shScramble and B16-F10 shMet exosomes.<list list-type="bullet"><list-item><p>Planned comparisons with the Bonferroni correction:<list list-type="order"><list-item><p>Total MET in B16-F10 shScramble exosomes compared to B16-F10 shMet exosomes</p></list-item><list-item><p>Phospho-MET in B16-F10 shScramble exosomes compared to B16-F10 shMet exosomes</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of effect sizes:<list list-type="bullet"><list-item><p>Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper, and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-6"><title>Known differences from the original study</title><p>The cell lines when not used in experimental procedures will be maintained under puromycin selection. The replication attempt will include an additional exosome marker, CD63, not included in the original study. All known differences are listed in the Materials and reagents section above with the originally used item listed in the Comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. This protocol analyzes the knockdown efficiency of c-Met in B16-F10 cells. Isolated exosomes are characterized by NanoSight and are analyzed for typical exosome markers by Western blot, including CD63, an additional marker not included in the original study. All of the raw data, including the image files and quantified bands from the Western blot, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/ewqzf/">https://osf.io/ewqzf/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-3"><title>Protocol 3: Exosome-dependent MET signaling on primary tumor growth and metastasis</title><p>This experiment tests the effect of exosome-derived MET on primary growth and metastasis of melanoma cells. This is a replication of Figure 4E, which assesses metastasis in lungs and bone using bioluminescent imaging.</p><sec id="s2-3-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment will use seven mice per cohort for a minimum power of 82%.<list list-type="bullet"><list-item><p>See Appendix for detailed power calculations</p></list-item></list></p></list-item><list-item><p>Each experiment has three cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Synthetic unilamellar liposomes injected into C57BL/6 mice</p></list-item><list-item><p>Cohort 2: B16-F10 shScramble exosomes injected into C57BL/6 mice</p></list-item><list-item><p>Cohort 3: B16-F10 shMet exosomes injected into C57BL/6 mice</p></list-item></list></p></list-item></list></sec><sec id="s2-3-2"><title>Materials and reagents</title><p><table-wrap id="tblu3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>B16-F10 shScramble cells</td><td>Cell line</td><td>n/a</td><td>n/a</td><td>Generated in Protocol 1</td></tr><tr><td>B16-F10 shMet cells</td><td>Cell line</td><td>n/a</td><td>n/a</td><td>Generated in Protocol 1</td></tr><tr><td>Dulbecco’s modified Eagle’s <break/>medium (DMEM)</td><td>Cell culture</td><td>VWR</td><td>45000-30</td><td>Communicated by authors; <break/>for B16-F10 shScramble <break/>and shMet cells</td></tr><tr><td>DMEM</td><td>Cell culture</td><td>Life Technologies</td><td>11995-040</td><td>Communicated by authors; <break/>for B16-F10-luciferase cells</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>GE Healthcare (HyClone)</td><td>SH30088.03</td><td>Original catalog number <break/>not specified</td></tr><tr><td>100X Penicillin/streptomycin</td><td>Cell culture</td><td>Life Technologies</td><td>15240-062</td><td>Communicated by authors</td></tr><tr><td>150 mm tissue culture dish</td><td>Labware</td><td>E &amp; K Scientific</td><td>EK-39160</td><td>Original brand not specified</td></tr><tr><td>10 mm tissue culture dish</td><td>Labware</td><td>Fisher Scientific</td><td>08-772-4F</td><td>Original brand not specified</td></tr><tr><td>T75 tissue culture flasks</td><td>Labware</td><td>Sigma-Aldrich</td><td>CLS430641</td><td>Originally not specified</td></tr><tr><td>T25 tissue culture flasks</td><td>Labware</td><td>Sigma-Aldrich</td><td>C6356</td><td>Originally not specified</td></tr><tr><td>50 ml centrifuge tubes</td><td>Labware</td><td>Fisher Scientific</td><td>14-959-49A</td><td>Original brand not specified</td></tr><tr><td>Ultracentrifuge</td><td>Instrument</td><td>Sorval</td><td/><td>SureSpin 630 rotor</td></tr><tr><td>Thick wall ultracentrifuge tubes</td><td>Labware</td><td colspan="3">Specific brand information will be left up to the discretion of the replicating lab <break/>and recorded later</td></tr><tr><td>Phosphate buffered saline (PBS)</td><td>Buffer</td><td>Fisher Scientific or <break/>Life Technologies</td><td>MT-21-040-CM or 70011-044</td><td>Replaces VWR, cat# 45000-446 <break/>Communicated by authors</td></tr><tr><td>Trypsin</td><td>Cell culture</td><td>Invitrogen or <break/>Life Technologies</td><td>25200-056 or 12604-021</td><td>Original brand not specified</td></tr><tr><td>Bicinchoninic acid (BCA) <break/>protein determination kit</td><td>Reporter assay</td><td>Pierce</td><td>23227</td><td>Original catalog number <break/>not specified</td></tr><tr><td>Nanoparticle characterization <break/>system</td><td>Instrument</td><td>NanoSight</td><td>LM10</td><td/></tr><tr><td>Nanoparticle Tracking Analysis</td><td>Software</td><td>NanoSight</td><td>Version 2.3</td><td>Original version not specified</td></tr><tr><td>Synthetic unilamellar <break/>100 nm liposomes</td><td>Chemical</td><td>Encapsula <break/>NanoSciences</td><td>n/a</td><td>Composition: 13 mg/ml <break/>L-α-phosphatidylcholine, <break/>2.78 mg/ml cholesterol <break/>(7:3 molar ratio P:C); <break/>communicated by authors</td></tr><tr><td>6-week-old C57BL/6 female mice</td><td>Animal model</td><td>Charles River</td><td>Strain code: 027</td><td>Replaces Jackson Laboratories used <break/>in the original study; age <break/>communicated by authors</td></tr><tr><td>B16-F10-luciferase cells</td><td>Cell line</td><td>Original lab</td><td>n/a</td><td>From original lab</td></tr><tr><td>1 ml syringe with Luer-Lok tip</td><td>Labware</td><td>Fisher Scientific</td><td>14-823-30</td><td>Original brand not specified</td></tr><tr><td>Needle</td><td>Labware</td><td colspan="3">Specific brand information will be left up to the discretion of the replicating lab <break/>and recorded later</td></tr><tr><td>3/10 cc syringe with 29G1/2 <break/>attached needle</td><td>Labware</td><td>Terumo Medical <break/>Products</td><td>SS30M2913</td><td>Original brand not specified</td></tr><tr><td>AErrane (Isoflurane)</td><td>Chemical</td><td>Baxter</td><td>n/a</td><td>Replaces original from Baxter, <break/>catalog # 400-326-09; <break/>communicated by authors</td></tr><tr><td>Oxygen</td><td>Chemical</td><td>Praxair</td><td>TC 3AAM 154</td><td>Replaces original from Airgas; <break/>communicated by authors</td></tr><tr><td>D-luciferin, potassium salt</td><td>Reporter assay</td><td>Biosynth</td><td>L-8220</td><td>Replaces original brand from <break/>Life Technologies; <break/>communicated by authors</td></tr><tr><td>IVIS Spectrum system</td><td>Instrument</td><td>Xenogen (Caliper)</td><td/><td/></tr><tr><td>Living Image software</td><td>Software</td><td>Xenogen (Caliper)</td><td>Version 4.2</td><td/></tr></tbody></table></table-wrap></p><p>Note:</p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble stable cells were generated in Protocol 1.</p></list-item><list-item><p>All cells maintained in DMEM supplemented with 10% exosome-depleted FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble stable cells should have 1.5 µg/ml puromycin added to medium while maintaining the cell lines that are not used in the experimental procedure.</p></list-item><list-item><p>The original study indicated mice were 8–10 weeks old, however the authors clarified that the mice were 6 weeks old.</p></list-item></list><list list-type="order"><list-item><p>Deplete exosomes from FBS by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Two–three days before needing exosomes, plate ~5 x 10<sup>6</sup> B16-F10 shScramble and B16-F10 shMet cells per 150 mm dish with 25 ml of media for exosome purification.<list list-type="alpha-lower"><list-item><p>Use three to six dishes per cell line to obtain needed amount of exosomes.</p></list-item><list-item><p>B16-F10 shMet and B16-F10 shScramble cells do not need puromycin added to plates used in the experimental procedure.</p></list-item></list></p></list-item><list-item><p>Culture cells exponentially for 48–72 hr until cells reach 80–90% confluence.</p></list-item><list-item><p>Purify exosomes from 150 mm dishes:<list list-type="alpha-lower"><list-item><p>Collect supernatant from cell cultures in 50 ml centrifuge tubes.</p></list-item><list-item><p>Pellet cells from supernatant in a benchtop centrifuge at 500x<italic>g</italic> for 10 min at 4˚C.</p></list-item><list-item><p>Transfer supernatant to thick wall ultracentrifuge tubes.</p></list-item><list-item><p>Remove cell debris by ultracentrifugation at 20,000x<italic>g</italic> for 20 min at 4˚C.</p></list-item><list-item><p>Collect supernatant.</p></list-item><list-item><p>Harvest exosomes by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Resuspend the exosome pellet in 20 ml of PBS.</p></list-item><list-item><p>Pellet exosomes by ultracentrifugation at 100,000x<italic>g</italic> for 70 min at 4˚C.</p></list-item><list-item><p>Resuspend exosome pellet in 100 µl PBS.<list list-type="roman-lower"><list-item><p>An aliquot of the exosome preparation can be stored at -20˚C until Nanosight analysis.</p></list-item></list></p></list-item><list-item><p>Measure protein concentration with a BCA kit following manufacturer’s instructions.<list list-type="roman-lower"><list-item><p>Estimated yield of exosomes should be around 1–2 µg/1x10<sup>6</sup> cells.</p></list-item></list></p></list-item><list-item><p>Characterize exosome pellets using standard Nanosight NTA analysis.<list list-type="roman-lower"><list-item><p>An aliquot of each exosome preparation will be stored at -20˚C and analyzed all at once following the final preparation.</p></list-item><list-item><p>10–20 µg of exosome protein is needed for analysis.</p></list-item><list-item><p>Report on size distribution and concentration of exosomes.</p></list-item><list-item><p>Report the number of exosomes per µg protein (as measured by BCA) for each sample.</p></list-item></list></p></list-item><list-item><p>Prepare samples at a concentration of 50 ng/µl to achieve 5 µg of total protein diluted in 100 µl of PBS.</p></list-item></list></p></list-item><list-item><p>Following protein quantification of each preparation, inject intravenously, via retro-orbital injection, freshly isolated B16-F10 shScramble or B16-F10 shMet exosomes, or synthetic unilamellar 100 nm liposomes into 6-week-old C57BL/6 female mice three times a week for a total of 28 d.<list list-type="alpha-lower"><list-item><p>Sample injection schedule:<list list-type="roman-lower"><list-item><p>Each cohort will be injected on Monday, Wednesday, and Friday with a fresh exosome preparation (&gt;35 µg total) each week for a total of 4 weeks.</p></list-item><list-item><p>Step 4 will be performed for each injection day.</p></list-item></list></p></list-item><list-item><p>It is crucial to inject fresh exosomes every time, do not freeze down, and inject right after purification and quantification following steps 2–4 above.</p></list-item><list-item><p>Volume of injection is 100 µl.</p></list-item><list-item><p>Amount of synthetic liposomes injected, 1.25 µg of L-α-phosphatidylcholine (PC) will mimic 5 µg of exosome protein, which is based on a theoretical 4:1 protein:PC ratio (communicated by authors).<list list-type="roman-lower"><list-item><p>Dilute 1.92 µl of a 1:20 dilution of the stock concentration of synthetic liposomes into 100 µl PBS for each injection.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>After 28 d, inject 1 x 10<sup>6</sup> B16-F10-luciferase cells diluted in 100 µl of PBS subcutaneously in the flank of mice.</p></list-item><list-item><p>Measure primary tumor volume three times a week for a total of 21 d.<list list-type="alpha-lower"><list-item><p>Use calipers to measure width and height with volume determined as (length x width<sup>2</sup>)/2. (additional recorded information)<list list-type="roman-lower"><list-item><p>Note: tumor volume detection will be limited to &lt;1000 mm<sup>3</sup>.</p></list-item></list></p></list-item><list-item><p>Record latency. (additional recorded information)<list list-type="roman-lower"><list-item><p>Note: Perform Steps 8 through 10 (luciferin injection, euthanasia, dissection, and imaging) from mice from different cohorts in parallel (i.e., one from each of the three cohorts) so variation during the procedure is equal across cohorts. (additional detail)</p></list-item></list></p></list-item></list></p></list-item><list-item><p>After 21 d anesthetize mice and inject 50 mg/kg of D-luciferin via retro-orbital injection in 100–200 µl PBS (volume depending on the body weight).<list list-type="alpha-lower"><list-item><p>Weigh mice.</p></list-item><list-item><p>Use isoflurane and O<sub>2</sub> to anesthetize mice.</p></list-item></list></p></list-item><list-item><p>Five min later euthanize mice by cervical dislocation under anesthesia and dissect tissues (lungs and femurs).<list list-type="alpha-lower"><list-item><p>Dissect out primary tumors and record weight (additional parameter).</p></list-item></list></p></list-item><list-item><p>Image dissected primary lungs and bones (femurs) for luciferase expression in IVIS Imaging system<list list-type="alpha-lower"><list-item><p>Record the time from euthanasia to imaging for each mouse.</p></list-item><list-item><p>Record photon flux.<list list-type="alpha-lower"><list-item><p>Take two–three exposure times for each sample.<list list-type="roman-lower"><list-item><p>Use same exposure time for each tissue from all mice during analysis.</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-3-3"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Mouse health records (injection schedule, time from tumor cell injection to detectable tumors [latency], weight of mice at end of experiment, mortality report)</p></list-item><list-item><p>Exosome characterization data (including protein concentration using a BCA kit).</p></list-item><list-item><p>Raw numbers and calculated tumor volume for all mice, and graph of tumor volume versus time for all conditions during course of treatment.</p></list-item><list-item><p>Time of euthanasia to imaging for each mouse.</p></list-item><list-item><p>Images of lungs and bones for luciferase expression (compare to Figure 4E).</p></list-item><list-item><p>Raw photon flux values of all analyzed images of each tissue for all conditions using the same exposure time (compare to Figure 4E).</p></list-item><list-item><p>Final weight of tumors.</p></list-item></list></p></list-item></list></sec><sec id="s2-3-4"><title>Confirmatory analysis plan</title><p>This experiment assesses if knockdown of Met alters primary tumor growth and metastasis. This replication attempt will perform the following statistical analysis:</p><list list-type="bullet"><list-item><p>Statistical Analysis:<list list-type="bullet"><list-item><p>Bonferroni corrected one-way ANOVAs comparing lung photon flux of mice treated with synthetic unilamellar liposomes, or exosomes from B16-F10 shScramble or B16-F10 shMet cells and the following planned comparisons with the Fisher’s least significant difference (LSD) test:<list list-type="order"><list-item><p>Synthetic unilamellar liposomes compared to B16-F10 shScramble exosomes</p></list-item><list-item><p>B16-F10 shMet exosomes compared to B16-F10 shScramble exosomes</p></list-item></list></p></list-item><list-item><p>Bonferroni corrected Kruskal–Wallis test comparing bone photon flux of mice treated with synthetic unilamellar liposomes, or exosomes from B16-F10 shScramble or B16-F10 shMet cells and the following planned comparisons (Wilcoxon–Mann–Whitney test) with the Fisher’s LSD test:<list list-type="order"><list-item><p>Synthetic unilamellar liposomes compared to B16-F10 shScramble exosomes</p></list-item><list-item><p>B16-F10 shMet exosomes compared to B16-F10 shScramble exosomes</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of effect sizes:<list list-type="bullet"><list-item><p> Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item><list-item><p>Exploratory analysis:<list list-type="bullet"><list-item><p> Comparison of primary tumor growth rates.<list list-type="bullet"><list-item><p>This is exploratory analysis. We will measure tumor growth rates across all mouse cohorts over the length of the study. These data were collected, but not reported in the original study, and found to not be different. We will plot growth curves and calculate area under the curve for each mouse. We will then perform a one-way analysis of variance (ANOVA) analysis, with the following planned comparisons with the Fisher’s LSD test:<list list-type="order"><list-item><p>Synthetic unilamellar liposomes compared to B16-F10 shScramble exosomes</p></list-item><list-item><p>B16-F10 shMet exosomes compared to B16-F10 shScramble exosomes</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Comparison of final primary tumor weights.<list list-type="bullet"><list-item><p>This is exploratory analysis. We will measure tumor weights across all mouse cohorts at the end of the study. These data were not reported in the original study. We will perform a one-way ANOVA analysis, with the following planned comparisons with the Fisher’s LSD test:<list list-type="order"><list-item><p>Synthetic unilamellar liposomes compared to B16-F10 shScramble exosomes</p></list-item><list-item><p>B16-F10 shMet exosomes compared to B16-F10 shScramble exosomes</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-3-5"><title>Known differences from the original study</title><p>The cell lines when not used in experimental procedures will be maintained under puromycin selection. The number of exosomes injected (based on protein content) will be reported for each preparation from each cohort. The original data on primary tumor growth were not shown and final primary tumor weights were not recorded. The replication attempt will record and present these data as well as tumor latency. All known differences are listed in the Materials and reagents section above with the originally used item listed in the Comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-3-6"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Isolated exosomes will be injected immediately after protein quantification and will be characterized by NanoSight following the final preparation to ensure the integrity of the samples. Exosomes and luciferin will be injected intravenously, via retro-orbital injection, similar to the original study. While it will be attempted to be the same for all animals, the time from euthanasia to imaging for each mouse will be recorded as an additional quality control parameter. All of the raw data, including the image files and photo flux values, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/ewqzf/">https://osf.io/ewqzf/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-4"><title>Power calculations</title><p>For additional details on power calculations, please see analysis scripts and associated files on the OSF: </p><p><ext-link ext-link-type="uri" xlink:href="https://osf.io/nyb8d/?view_only%20=%2076b131dfea3c4cfeb60965a6ad94b8ae">https://osf.io/nyb8d/</ext-link></p> <sec id="s2-4-1"><title>Protocol 1</title><p>Not applicable</p></sec><sec id="s2-4-2"><title>Protocol 2</title><p>Summary of original data reported in Figure S5A (calculated from data shared by original authors):</p><p><table-wrap id="tblu4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset being analyzed</th><th/><th>Mean</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td rowspan="2">Total MET</td><td>B16-F10 shScramble cells</td><td>1.000</td><td>0.0085</td><td>2</td></tr><tr><td>B16-F10 shMet cells</td><td>0.641</td><td>0.0254</td><td>2</td></tr><tr><td rowspan="2">Phospho-MET</td><td>B16-F10 shScramble cells</td><td>1.000</td><td>0.0318</td><td>2</td></tr><tr><td>B16-F10 shMet cells</td><td>0.234</td><td>0.0134</td><td>2</td></tr></tbody></table></table-wrap></p><p>The replication will also include analysis of total MET and phospho-MET in exosomes from B16-F10 shScramble and B16-F10 shMet cells. We will use the same calculated sample size as determined for the cells with the assumption that the cells and exosomes have similar values, which Peinado and colleagues (2012) present in Figure 4A.</p><p>Test family</p><list list-type="bullet"><list-item><p>two-tailed <italic>t</italic> test, difference between two independent means, Bonferroni’s correction: alpha error = 0.025</p></list-item></list><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib2">Faul et al., 2007</xref>).</p><p>Total Met:</p><p><table-wrap id="tblu5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th> <th>A priori power</th><th>Group 1 <break/>sample size</th><th>Group 2 <break/>sample size</th></tr></thead><tbody><tr><td>B16-F10 shScramble</td><td>B16-F10 shMet</td><td>18.97367</td><td>99.9%</td><td>2*</td><td>2*</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>* A minimum sample size of three per group will be used making the power 99.9%</p></fn></table-wrap-foot></table-wrap></p><p>Phospho-Met:</p><p><table-wrap id="tblu6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th> <th>A priori power</th><th>Group 1 <break/>sample size</th><th>Group 2 <break/>sample size</th></tr></thead><tbody><tr><td>B16-F10 shScramble</td><td>B16-F10 shMet</td><td>31.38411</td><td>99.9%</td><td>2<sup>†</sup> </td><td>2<sup>†</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p><sup>†</sup> A minimum sample size of three per group will be used making the power 99.9%.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-4-3"><title>Protocol 3</title><p>Summary of original data reported in Figure 4E (calculated from data shared by original authors):</p><p><table-wrap id="tblu7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset being analyzed</th><th/><th>Mean</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td rowspan="3">Lung photon flux</td><td>Synthetic unilamellar liposomes</td><td>23,386</td><td>9,138</td><td>7</td></tr><tr><td>Exosomes from B16-F10 shScramble cells</td><td>50,771</td><td>14,966</td><td>7</td></tr><tr><td>Exosomes from B16-F10 shMet cells</td><td>12,667</td><td>9,032</td><td>7</td></tr><tr><td rowspan="3">Bones photon flux</td><td>Synthetic unilamellar liposomes</td><td>0</td><td>0</td><td>5</td></tr><tr><td>Exosomes from B16-F10 shScramble cells</td><td>44,660</td><td>32,595</td><td>5</td></tr><tr><td>Exosomes from B16-F10 shMet cells</td><td>0</td><td>0</td><td>5</td></tr></tbody></table></table-wrap></p><p>Lung photo flux:</p><p>Test family</p><list list-type="bullet"><list-item><p>ANOVA: Fixed effects, omnibus, one-way, Bonferroni’s correction: alpha error = 0.025.</p></list-item></list><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib2">Faul et al., 2007</xref>).</p><p>ANOVA F-test statistic performed with R software, version 3.1.2 (<xref ref-type="bibr" rid="bib8">Team, 2014</xref>).</p><p>Partial η<sup>2</sup> calculated from (<xref ref-type="bibr" rid="bib5">Lakens, 2013</xref>).</p><p><table-wrap id="tblu8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset</th><th>Groups</th><th>F-test statistic</th><th>Partial η<sup>2</sup></th><th>Effect <break/>size <italic>f</italic></th> <th>A priori <break/>power</th><th>Total sample <break/>size</th></tr></thead><tbody><tr><td>Lung</td><td>Synthetic unilamellar <break/>liposomes, <break/>B16-F10 shScramble, <break/>B16-F10 shMet</td><td>F(2,18) = 20.8417</td><td>0.69841</td><td>1.52176</td><td>94.8%*</td><td>12 total mice* <break/>(3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><p>* 21 total mice will be used based on the bones photon flux planned comparison calculations making the power 99.9%.</p></fn></table-wrap-foot></table-wrap></p><p>Test family</p><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, difference between two independent means, Fisher’s LSD correction: alpha error = 0.025.</p></list-item></list><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib2">Faul et al., 2007</xref>).</p><p><table-wrap id="tblu9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect <break/>size <italic>d</italic></th> <th>A priori <break/>power</th><th>Group 1 <break/>sample size</th><th>Group 2 <break/>sample size</th></tr></thead><tbody><tr><td>Synthetic unilamellar <break/>liposomes</td><td>B16-F10 shScramble</td><td>2.20861</td><td>86.1%</td><td>6*</td><td>6*</td></tr><tr><td>B16-F10 shScramble</td><td>B16-F10 shMet</td><td>3.08277</td><td>87.6%</td><td>4<sup>†</sup></td><td>4<sup>†</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p>* 7 mice will be used per group based on the bones photon flux calculations making the power 92.5%.</p></fn><fn id="tblfn5"><p><sup>†</sup> 7 mice will be used per group based on the bones photon flux calculations making the power 99.8%.</p></fn></table-wrap-foot></table-wrap></p><p>Bones photon flux:</p><p>Test family</p><list list-type="bullet"><list-item><p>ANOVA: Fixed effects, omnibus, one-way, Bonferroni’s correction: alpha error = 0.025.</p></list-item></list><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib2">Faul et al., 2007</xref>). ANOVA F-test statistic performed with R software, version 3.1.2 (<xref ref-type="bibr" rid="bib8">Team, 2014</xref>). Partial η<sup>2</sup> calculated from (<xref ref-type="bibr" rid="bib5">Lakens, 2013</xref>).</p><p><table-wrap id="tblu10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset</th><th>Groups</th><th>F-test statistic</th><th>Partial η<sup>2</sup></th><th>Effect size <italic>f</italic></th> <th>A priori <break/>power</th><th>Total <break/>sample size</th></tr></thead><tbody><tr><td>Bones</td><td>Synthetic unilamellar <break/>liposomes, <break/>B16-F10 shScramble, <break/>B16-F10 shMet</td><td>F(2,12) = 9.3866</td><td>0.61005</td><td>1.25077</td><td>82.2%* </td><td>12* <break/>(3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p>* Since the nonparametric Kruskal–Wallis test will be performed for the analysis instead of an ANOVA, a 15% adjustment in sample size (15 instead of 12) is taken into account. A total of 21 mice will be used based on the bones photon flux planned comparison calculations making the power 98.1% (using a 15% adjusted sample size of 18 instead of 21).</p></fn></table-wrap-foot></table-wrap></p><p>Test family</p><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, Wilcoxon–Mann–Whitney test (two groups), Fisher’s LSD correction: alpha error = 0.025.</p></list-item></list><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib2">Faul et al., 2007</xref>).</p><p><table-wrap id="tblu11" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th> <th>A priori power</th><th>Group 1 <break/>sample size</th><th>Group 2 <break/>sample size</th></tr></thead><tbody><tr><td>Synthetic unilamellar <break/>liposomes</td><td>B16-F10 shScramble</td><td>1.93769</td><td>81.6%</td><td>7</td><td>7</td></tr><tr><td>B16-F10 shScramble</td><td>B16-F10 shMet</td><td>1.93769</td><td>81.6%</td><td>7</td><td>7</td></tr></tbody></table></table-wrap></p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Hector Peinado, for generously sharing critical information as well as reagents to ensure the fidelity and quality of this replication attempt. We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We thank Maureen Peterson at System Biosciences for help with some protocol details. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology: American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).</p></ack><sec id="s3" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>JL: System Biosciences Inc., is a Science Exchange associated lab. System Biosciences produces some of the reagents used in this study, specifically TransDux, and the rabbit anti-CD63 antibody.</p></fn><fn fn-type="conflict" id="conf2"><p>TA: System Biosciences Inc., is a Science Exchange associated lab. System Biosciences produces some of the reagents used in this study, specifically TransDux, and the rabbit anti-CD63 antibody.</p></fn><fn fn-type="conflict" id="conf3"><p>JK: This is a Science Exchange associated lab.</p></fn><fn fn-type="conflict" id="conf4"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>JL, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>TA, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>JK, Transgenic Research Center is a Science Exchange associated lab., Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>EG, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>LP, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><elocation-id>e5773</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>A-G</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gherardi</surname><given-names>E</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name><name><surname>Woude</surname><given-names>GV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Targeting MET in cancer: rationale and progress</article-title><source>Nature Reviews Cancer</source><volume>12</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nrc3205</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharaziha</surname><given-names>P</given-names></name><name><surname>Ceder</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Panaretakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tumor cell-derived exosomes: a message in a bottle</article-title><source>Biochimica Et Biophysica Acta</source><volume>1826</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2012.03.006</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakens</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs</article-title><source>Frontiers in Psychology</source><volume>4</volume><fpage>863.</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2013.00863</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathivanan</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Simpson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Exosomes: extracellular organelles important in intercellular communication</article-title><source>Journal of Proteomics</source><volume>73</volume><fpage>1907</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2010.06.006</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>Alečković</surname><given-names>M</given-names></name><name><surname>Lavotshkin</surname><given-names>S</given-names></name><name><surname>Matei</surname><given-names>I</given-names></name><name><surname>Costa-Silva</surname><given-names>B</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G</given-names></name><name><surname>Hergueta-Redondo</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>García-Santos</surname><given-names>G</given-names></name><name><surname>Ghajar</surname><given-names>CM</given-names></name><name><surname>Nitadori-Hoshino</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>C</given-names></name><name><surname>Badal</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>VR</given-names></name><name><surname>Skog</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RN</given-names></name><name><surname>Brady</surname><given-names>MS</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Bromberg</surname><given-names>J</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</article-title><source>Nature Medicine</source><volume>18</volume><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1038/nm.2753</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>R Development Core Team R</collab></person-group><year iso-8601-date="2014">2014</year><article-title>A language and environment for statistical computing</article-title><source>R Foundation for Statistical Computing.</source><uri xlink:href="http://www. R-project.org/">http://www. R-project.org/</uri></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tickner</surname><given-names>JA</given-names></name><name><surname>Urquhart</surname><given-names>AJ</given-names></name><name><surname>Stephenson</surname><given-names>S-A</given-names></name><name><surname>Richard</surname><given-names>DJ</given-names></name><name><surname>O'Byrne</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functions and therapeutic roles of exosomes in cancer</article-title><source>Frontiers in Oncology</source><volume>4</volume><fpage>13.</fpage><pub-id pub-id-type="doi">10.3389/fonc.2014.00127</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MET signalling: principles and functions in development, organ regeneration and cancer</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>11</volume><fpage>834</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1038/nrm3012</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.07383.002</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Green</surname><given-names>Michael R</given-names></name><role>Reviewing editor</role><aff id="aff12"><institution>Howard Hughes Medical Institute, University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Registered report: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET&quot; for peer review at <italic>eLife</italic>. Your submission has been favorably evaluated by Charles Sawyers (Senior Editor), Michael Green (Reviewing Editor), and four reviewers, one of whom, John Harris, has agreed to reveal his identity.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Although the reviewers were generally positive there were several substantive concerns that need to be addressed in a revised registered report. Of particular concern is the method used for exosome isolation (point 1) and the apparent conflict of interest (point 2).</p><p>Essential revisions:</p><p>1) Given the aim of this project, it is of paramount importance that all details of the experimental design be reproduced as described in Peinado et al., Nature Medicine, 2012. In particular, there are some critical differences in the experimental procedures of the proposed study that may lead to big differences in the results compared to the original Peinado et al. study. First and foremost, the method proposed to isolate exosomes for western blot and functional studies, as well as for the depletion of exosomes from FBS is based on ExoQuick extraction rather than sequential ultracentrifugation as in the original publication. This is a major issue that can hinder the reproducibility of the data, as during exosome isolation using ExoQuick, contaminants (e.g. VEGF) are trapped by ExoQuick, therefore education would not be strictly and solely due to exosomes. Clearly the authors are aware of this issue, as they have highlighted this difference. The main problem is that 1 μg of exosomal protein from ExoQuick-isolated exosomes would be the equivalent of 0.1-0.5 μg of exosomes isolated by classical ultracentrifugation (UC), as in the Peinado et al. study. This 10-fold difference in the amount of exosome protein delivered in education studies would lead to &quot;under-education&quot;. Since in the Peinado et al. study the exosomal preparations were free of contaminants, as demonstrated by electron microscopy and western blot, and the authors' likely carry significant contaminants, a side by side comparison of ExoQuick and ultracentrifugation would be required to determine the amount of ExoQuick exosomal preparation equivalent to 10 μg of exosomes. A reference is not sufficient, actual data needs to be presented for this comparison, including quantitation and electron microscopy studies. The authors would have to measure the yield of exosomes, proteins and contaminants from both methods in parallel.</p><p>There are numerous publications presenting data comparing exosomal isolation methods that support the use of ultracentrifugation versus polymer-based precipitating methods such as ExoQuick. In particular, three papers demonstrate that up to 23 times more material is precipitated with ExoQuick compared to standard serial UC (Van Deun J et al., Journal of Extracellular Vesicles, 2014, 18(3), PMID: 25317274; Zlotogorski-Hurvitz A et al., J Histochem Cytochem. 2015, 63(3): 181-9, PMID: 25473095; Yamada T et al., J Vet Med Sci. 2012, 74(11):1523-5, PMID: 22785357). A recent study provides electron microscopy pictures that demonstrate that the higher protein yield obtained with the ExoQuick precipitation method compared to the UC gold standard is due to contaminants such as large protein aggregates (Sáenz-Cuesta M et al., Front Immunol, 2015, 6:50, PMID: 25762995).</p><p>2) Importantly, the fact that the first three authors on the proposed Reproducibility project study are employees of System Biosciences, the company that produces ExoQuick as well as ExoFBS raises a red flag and creates a huge conflict on interest in terms of the choice of methodology. The choice of experimental approaches and reagents should be driven by the desire to perform the tests in conditions as close as possible to the original study, but the authors are clearly choosing a critical reagent that introduces a large variation from the original study based on financial interests.</p><p>3) It is not clear whether the authors plan to use fresh or frozen (-20°C) exosomal preparations for education. There have been studies that have shown that freezing exosomes results in lysis of more than 50% of the preparation (Oosthuyzen et al., J Physiol. 2013, 591(Pt 23): 5833-5842) which will affect the amount delivered in a single dose (if the exosomes were quantified prior to freezing and that amount is used for calculation of material to inject for education). Freezing could also affect the functionality of exosomes. The original Peinado et al. study had performed the education studies with fresh exosomes.</p><p>4) Another major problem is that the authors are using non-transduced B16-F10 cells as control for the B16-F10 shMET. It is highly recommended that a scrambled short hairpin control (shScramble) be used, as it is widely known that infection and puromycin treatment of cells may alter the cell population and the appropriate scrambled control in the same vector is available from the same company that produces the shMET. Importantly, the authors plan to rely solely on puromycin resistance to select the knockdown clones, but this is not sufficient to isolate a pure population of transduced cells that maintains high levels of vector integration and expression. In addition to verifying knockdown of MET, the authors also need to show that Met knockdown did not affect the growth of the cells (every integration event is unique and you never know where the lentivirus integrated).</p><p>5) In protocol 1: The authors propose to use puromycin selection to generate stable B16-F10 shMet transfectants instead of FACS sorting GFP-positive cells, which should be sufficient. Upon reviewing the original paper, we could not find any details how the authors generated B16-F10 shMet cells, and whether these were stable transfectants. Was this communicated directly by the authors of the study?</p><p>6) It looks like they never tested whether MET was downregulated in exosomes themselves in supplementary Figure 5a, just in the parent cells from which they purified the exosomes. This is planned for the B16-F10 control and shMET exosomes, which we think is good. We would also suggest including B16-F1 exosomes, as there was a comparison by Western blot for the B16-F10 to B16-F1 exosomes in Figure 4a, at least that would be something to compare across studies.</p><p>7) In the original paper there is a microarray analysis where genes with a fold change greater than 2 are reported. Apparently p-values from a t-test were computed with a permutation approach but not reported. It would be interesting to repeat also this experiment reporting the statistical significant genes controlling the false discovery rate.</p><p>8) In the statistical analyses plan of the report it is claimed that Fisher's LSD correction has been used. However the alpha error 0.025 reported is due to a Bonferroni's correction; indeed the Fisher's LSD correction used by the authors is not taking into account that multiple comparisons will be performed and it's good only for the calculation of the effect size (see Anthony J. Hayter. The maximum familywise error rate of fisher's least significant difference test. Journal of the American Statistical Association, 1986, 81(396):</p><p>1000-1004, doi: 10.1080/01621459.1986.10478364).</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Registered report: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET&quot; for further consideration at <italic>eLife</italic>. Your revised article has been evaluated by Charles Sawyers (Senior Editor), Michael Green (Reviewing Editor), and four reviewers, one of whom, John Harris, has agreed to reveal his identity.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>The reviewers felt that the revised manuscript had been considerably improved. However, two major problems remain. First, given the aim of this project, it is of paramount importance that all details of the experimental design be reproduced as described in Peinado et al., Nature Medicine, 2012. Therefore, all of the reviewers feel strongly that exosome purification needs to be done by sequential ultracentrifugation as in Peinado et al. (see point 1). Second, the conflict of issue has not been adequately resolved (see point 2).</p><p>Essential revisions:</p><p>1) We appreciate the authors' efforts to address my concerns. However, the new experiment (protocol 3) added to the manuscript proposing to compare ExoQuick extraction with the sequential ultracentrifugation presented in the original publication, is not appropriate for the &quot;Reproducibility project&quot;. This is a new experiment that can be the focus of a new manuscript. Even for such a method comparison manuscript, to indeed validate their side-by-side comparison of ExoQuick and ultracentrifugation, the authors should perform unbiased analyses, specifically proteomic analysis of exosomes by mass spectrometry, not just western blot analyses. For the purpose of reproducing the data in the original Peinado et al. publication, the original exosome purification method should be used. Despite the fact that the differences from the original study are clearly stated for each protocol, for Protocols 2 and 4, the authors are still relying ONLY on ExoQuick for exosome purification. Given that during exosome isolation using ExoQuick, contaminants (e.g. VEGF) are trapped by ExoQuick, and the fact that education would not be strictly and solely due to exosomes, we believe that all the experiments proposed in this paper should be performed using the sequential ultracentrifugation, not ExoQuick. Moreover, the authors are using System Biosciences ExoFBS for all the experiments, rather than depleting exosomes from the FBS using sequential ultracentrifugation.</p><p>2) The authors declared their conflict of interest as employees of System Biosciences, the company that produces ExoQuick as well as ExoFBS. However, the determination of the authors to use System Biosciences reagents to conduct this study (even in the context of comparing methods) is impacted by the conflict of interest and driven by their desire to promote System Biosciences products. Therefore, because of their vested interest, employees of SBI should be excluded from the author list of this reproducibility project or the manuscript should not use any System Biosciences products.</p><p>3) The authors included the scrambled short hairpin control (shScramble) B16-F10 cells as s control for the B16-F10 shMET experiments. However, the authors plan to rely solely on puromycin resistance to select the knockdown clones, but this is not sufficient to isolate a pure population of transduced cells that maintains high levels of vector integration and expression. The authors should evaluate the knockdown after 28 days of puromycin selection. The authors should either use fluorescence-activated cell sorting to select a pure population or they should maintain the cells under puromycin selection. Just as another control, it would be desirable to compare both B16-F10 wild-type and Scramble in order to verify that the scramble does not have any undesirable effects, since infection can cause genome instability that way would be a perfect control.</p><p>4) The synthetic liposome control was a bit confusing. The authors say they will use 5 µg to match the protein on exosomes, but there should not be any protein on synthetic liposomes. We think they should figure out a vesicle concentration based on NanoSight and then use the same concentration of synthetic liposomes.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.07383.003</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) Given the aim of this project, it is of paramount importance that all details of the experimental design be reproduced as described in Peinado et al., Nature Medicine, 2012. In particular, there are some critical differences in the experimental procedures of the proposed study that may lead to big differences in the results compared to the original Peinado et al. study. First and foremost, the method proposed to isolate exosomes for western blot and functional studies, as well as for the depletion of exosomes from FBS is based on ExoQuick extraction rather than sequential ultracentrifugation as in the original publication. This is a major issue that can hinder the reproducibility of the data, as during exosome isolation using ExoQuick, contaminants (e.g. VEGF) are trapped by ExoQuick, therefore education would not be strictly and solely due to exosomes. Clearly the authors are aware of this issue, as they have highlighted this difference. The main problem is that 1 μg of exosomal protein from ExoQuick-isolated exosomes would be the equivalent of 0.1-0.5 μg of exosomes isolated by classical ultracentrifugation (UC), as in the Peinado et al. study. This 10-fold difference in the amount of exosome protein delivered in education studies would lead to &quot;under-education&quot;. Since in the Peinado et al. study the exosomal preparations were free of contaminants, as demonstrated by electron microscopy and western blot, and the authors' likely carry significant contaminants, a side by side comparison of ExoQuick and ultracentrifugation would be required to determine the amount of ExoQuick exosomal preparation equivalent to 10 μg of exosomes. A reference is not sufficient, actual data needs to be presented for this comparison, including quantitation and electron microscopy studies. The authors would have to measure the yield of exosomes, proteins and contaminants from both methods in parallel.</italic></p><p><italic>There are numerous publications presenting data comparing exosomal isolation methods that support the use of ultracentrifugation versus polymer-based precipitating methods such as ExoQuick. In particular, three papers demonstrate that up to 23 times more material is precipitated with ExoQuick compared to standard serial UC (Van Deun J et al., Journal of Extracellular Vesicles, 2014, 18(3), PMID: 25317274; Zlotogorski-Hurvitz A et al., J Histochem Cytochem. 2015, 63(3): 181-9, PMID: 25473095; Yamada T et al., J Vet Med Sci. 2012, 74(11):1523-5, PMID: 22785357). A recent study provides electron microscopy pictures that demonstrate that the higher protein yield obtained with the ExoQuick precipitation method compared to the UC gold standard is due to contaminants such as large protein aggregates (Sáenz-Cuesta M et al., Front Immunol, 2015 Feb 13;6:50; PMID: 25762995).</italic></p><p>We have included a comparison of the two methods, ultracentrifugation and ExoQuick, as a pilot experiment (protocol 3) to occur prior to the in vivo experiment. This will compare protein yield, exosome number, and contaminants. This will allow for an adjustment, if needed, in the amount of isolated protein used in the education study to control for any potential differences in the number of exosomes relative to protein content isolated by each method. This will allow for the proposed education experiment to use an equivalent number of exosomes from 5 µg of total protein when generated by ultracentrifugation.</p><p><italic>2) Importantly, the fact that the first three authors on the proposed Reproducibility project study are employees of System Biosciences, the company that produces ExoQuick as well as ExoFBS raises a red flag and creates a huge conflict on interest in terms of the choice of methodology. The choice of experimental approaches and reagents should be driven by the desire to perform the tests in conditions as close as possible to the original study, but the authors are clearly choosing a critical reagent that introduces a large variation from the original study based on financial interests.</italic></p><p>To address the concern regarding the experimental approach, we have included a comparison between methods to the revised manuscript as described in point 1 above. Additionally, any known differences are stated a priori. We have also included in the conflict of interest statement that System Biosciences produces the two reagents in question as well as the TransDux and the CD63 antibody.<italic>3) It is not clear whether the authors plan to use fresh or frozen (-20°C) exosomal preparations for education. There have been studies that have shown that freezing exosomes results in lysis of more than 50% of the preparation (Oosthuyzen et al., J Physiol. 2013,591(Pt 23): 5833-5842) which will affect the amount delivered in a single dose (if the exosomes were quantified prior to freezing and that amount is used for calculation of material to inject for education). Freezing could also affect the functionality of exosomes. The original Peinado et al. study had performed the education studies with fresh exosomes.</italic></p><p>The exosomes will be isolated, protein content determined, and used fresh for each injection. We have revised some of the language to attempt to make this clearer.</p><p><italic>4) Another major problem is that the authors are using non-transduced B16-F10 cells as control for the B16-F10 shMET. It is highly recommended that a scrambled short hairpin control (shScramble) be used, as it is widely known that infection and puromycin treatment of cells may alter the cell population and the appropriate scrambled control in the same vector is available from the same company that produces the shMET. Importantly, the authors plan to rely solely on puromycin resistance to select the knockdown clones, but this is not sufficient to isolate a pure population of transduced cells that maintains high levels of vector integration and expression. In addition to verifying knockdown of MET, the authors also need to show that Met knockdown did not affect the growth of the cells (every integration event is unique and you never know where the lentivirus integrated).</italic></p><p>We agree with this suggestion and have included the shScramble in the revised manuscript. It was not clear if it was used in Peinado et al. for Figure 4E where the cells were described as F10, not shScramble, unlike for the experiments reported in Figure 5 that describe the cells as shScramble.</p><p>The transduction efficiency (as monitored by GFP expression using fluorescent microscopy) will be recorded for each stable knockdown line and recorded. While sorting of the cells by FACS will not occur, the knockdown efficiency by western blot (protocol 2) will be compared to the original study to compare the achieved knockdown of the original and replication attempts. The revised manuscript includes additional details commenting on how detailed notes regarding cell passaging will be made available to assess if there are differences in cellular growth.</p><p><italic>5) In protocol 1: The authors propose to use puromycin selection to generate stable B16-F10 shMet transfectants instead of FACS sorting GFP-positive cells, which should be sufficient. Upon reviewing the original paper, we could not find any details how the authors generated B16-F10 shMet cells, and whether these were stable transfectants. Was this communicated directly by the authors of the study?</italic></p><p>Yes, this information was communicated directly by the authors of the original study. We have included additional text to highlight this.</p><p><italic>6) It looks like they never tested whether MET was downregulated in exosomes themselves in supplementary Figure 5a, just in the parent cells from which they purified the exosomes. This is planned for the B16-F10 control and shMET exosomes, which we think is good. We would also suggest including B16-F1 exosomes, as there was a comparison by Western blot for the B16-F10 to B16-F1 exosomes in Figure 4a, at least that would be something to compare across studies.</italic></p><p>Thank you for the suggestion. We had originally thought of including the B16-F1 exosomes as well, but considering the B16-F1 cells are not utilized elsewhere in the manuscript, we have not included it. While it would further help show that Met, and pMet, is present in B16-F10 cells with lower levels in B16-F1 cells, the shMet condition serves as the proper control for this. Additionally, since the B16-F1 and B16-F10 exosome comparison was not quantified in the original study, it is difficult to ascertain the relative level of Met or pMet in either cell line.</p><p><italic>7) In the original paper there is a microarray analysis where genes with a fold change greater than 2 are reported. Apparently p-values from a t-test were computed with a permutation approach but not reported. It would be interesting to repeat also this experiment reporting the statistical significant genes controlling the false discovery rate.</italic></p><p>We agree the microarray experiment would be interesting to replicate, however these types of experiments are excluded from all articles. These exclusion criteria are outlined on the project page (<ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies">https://osf.io/e81xl/wiki/studies</ext-link>) and in a Feature Article describing the project (<ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/content/3/e04333">http://elifesciences.org/content/3/e04333</ext-link>). We understand that the exclusion of certain experiments limits the scope of what can be analyzed by the project, but we are attempting to identify a balance of breadth of sampling for general inference with sensible investment of resources on replication projects to determine to what extent the included experiments are reproducible. As such, we will restrict our analysis to the experiments being replicated and will not include discussion of experiments not being replicated in this study.</p><p><italic>8) In the statistical analyses plan of the report it is claimed that Fisher's LSD correction has been used. However the alpha error 0.025 reported is due to a Bonferroni's correction; indeed the Fisher's LSD correction used by the authors is not taking into account that multiple comparisons will be performed and it's good only for the calculation of the effect size (see Hayter, 1986).</italic></p><p>The Bonferroni correction (making the alpha error 0.025) was to account for the two measurements (lung photon flux and bones photon flux) on the same animals since they will be performed using two different test families (ANOVA and Kruskal-Wallis). However, within each measurement and test family alpha error of 0.025, the comparisons use a Fisher’s LSD correction. We agree with the reviewers comment on the use of a correction, such as Bonferroni or the modification of LSD by Hayter, as ways to control for the MFWER, however as Hayter describes in his 1986 paper, this applies in situations where the ANOVA is unbalanced or with a balanced design with four or more populations. Since the proposed analysis is balanced with three population groups, the LSD is sufficiently conservative and powerful to account for the multiple comparisons in this specific situation. This is further explained by Levin et al., 1994 and discussed in Maxwell and Delaney, 2004 (Chapter 5) and Cohen, 2001 (Chapter 12).</p><p>References:</p><p>Levin, J.R., Serline, R.C., &amp; Seaman M.A. (1994). A controlled, powerful multiple-comparison strategy for several situations. Psychological Bulletin, 115, 153-159.</p><p>Maxwell, S.E. &amp; Delaney, H.D. (2004). Designing experiments and analyzing data: a model comparison perspecitive. Lawrence Erlbaum Associates, Mahwah, N.J., 2nd edition.</p><p>Cohen, B.H. (2001). Explaining psychological statistics. John Wiley and Sons, New York, 2nd edition.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p><italic>Essential revisions:</italic></p><p> <italic>1) We appreciate the authors' efforts to address my concerns. However, the new experiment (protocol 3) added to the manuscript proposing to compare ExoQuick extraction with the sequential ultracentrifugation presented in the original publication, is not appropriate for the &quot;Reproducibility project&quot;. This is a new experiment that can be the focus of a new manuscript. Even for such a method comparison manuscript, to indeed validate their side-by-side comparison of ExoQuick and ultracentrifugation, the authors should perform unbiased analyses, specifically proteomic analysis of exosomes by mass spectrometry, not just western blot analyses. For the purpose of reproducing the data in the original Peinado et al. publication, the original exosome purification method should be used. Despite the fact that the differences from the original study are clearly stated for each protocol, for Protocols 2 and 4, the authors are still relying ONLY on ExoQuick for exosome purification. Given that during exosome isolation using ExoQuick, contaminants (e.g. VEGF) are trapped by ExoQuick, and the fact that education would not be strictly and solely due to exosomes, we believe that all the experiments proposed in this paper should be performed using the sequential ultracentrifugation, not ExoQuick. Moreover, the authors are using System Biosciences ExoFBS for all the experiments, rather than depleting exosomes from the FBS using sequential ultracentrifugation.</italic></p><p>The revised manuscript includes the approach to purify exosomes by sequential ultracentrifugation instead of ExoQuick and as well as use FBS depleted of exosomes by ultracentrifugation as described in the original paper and confirmed by the original authors. Additionally, the protocol to compare ExoQuick to ultracentrifugation has been removed since it is no longer necessary for this replication attempt.</p><p> <italic>2) The authors declared their conflict of interest as employees of System Biosciences, the company that produces ExoQuick as well as ExoFBS. However, the determination of the authors to use System Biosciences reagents to conduct this study (even in the context of comparing methods) is impacted by the conflict of interest and driven by their desire to promote System Biosciences products. Therefore, because of their vested interest, employees of SBI should be excluded from the author list of this reproducibility project or the manuscript should not use any System Biosciences products.</italic></p><p>We hope the reviewers agree that with the above revisions the conflict of interest has been adequately resolved. There are still two reagents used in the study that are produced by System Biosciences, TransDux, which replaces polybrene during the transfection procedure, and the rabbit anti-CD63 antibody, which was added as an additional quality control measure not included in the original study. Both are listed in the competing interests statement. As a reminder, TransDux reagent is similar to polybrene and enables high transduction rates of virus into most cells, sometimes at higher rates than polybrene. Most importantly, the knockdown efficiency, which is partly reflected by the infection reagent used, will be reported for both cells and exosomes, and for at the least the cells, will be compared to the originally reported knockdown efficiency.</p><p> <italic>3) The authors included the scrambled short hairpin control (shScramble) B16-F10 cells as s control for the B16-F10 shMET experiments. However, the authors plan to rely solely on puromycin resistance to select the knockdown clones, but this is not sufficient to isolate a pure population of transduced cells that maintains high levels of vector integration and expression. The authors should evaluate the knockdown after 28 days of puromycin selection. The authors should either use fluorescence-activated cell sorting to select a pure population or they should maintain the cells under puromycin selection. Just as another control, it would be desirable to compare both B16-F10 wild-type and Scramble in order to verify that the scramble does not have any undesirable effects, since infection can cause genome instability that way would be a perfect control.</italic></p><p>The revised manuscript has the stable cells maintained in puromycin for at least 28 days prior to performing the knockdown evaluation. Additionally, the cells will remain under puromycin selection throughout maintenance of the cell lines, however when the cells are plated for experiments (for exosome purification) they will not include puromycin, which is similar to how exosomes were isolated in the original study.</p><p>We agree the addition of untransduced B16-F10 cells would be a valuable additional control to include. However, it is not feasible to include this extension to the original work since it is not possible to balance this additional aspect with the main aim of this project: to perform a direct replication of the original experiment(s).</p><p> <italic>4) The synthetic liposome control was a bit confusing. The authors say they will use 5 µg to match the protein on exosomes, but there should not be any protein on synthetic liposomes. We think they should figure out a vesicle concentration based on NanoSight and then use the same concentration of synthetic liposomes.</italic></p><p>Thank you for highlighting this detail. In communication with the original authors we obtained the original amount of synthetic liposome controls injected and have added it to the revised manuscript. The amount of liposomes to inject is based on a theoretical ratio of 4:1 protein:L-α-phosphatidylcholine. With a formulation of liposomes that is 13 mg/ml L-α-phosphatidylcholine, 2.78 mg/ml cholesterol (7:3 molar ratio) the control injections will use 1.25 µg L-α-phosphatidylcholine to mimic the 5 µg of exosomes injected.</p></body></sub-article></article>